



ASX ANNOUNCEMENT

26 October 2018

CardieX Wins Contract to Supply Medical Devices for International Pharmaceutical Trial

Highlights:

- CardieX subsidiary to supply SphygmoCor® systems in new clinical trial.
- Study will be multinational assessing heart failure treatment.
- AstraZeneca AB group are managing the trial.
- Trial to run for 18 months across US and Europe.
- Cost of heart failure to US circa US\$30 billion annually.
- Trial seen as first phase of larger commercial opportunity for CardieX group.

CardieX Limited (ASX: CDX), announced earlier today that its AtCor Medical subsidiary has executed a new contract to supply SphygmoCor® systems and clinical trial support services in a multinational clinical study that will assess the central hemodynamic effects of a novel compound for the treatment of heart failure.

Following the announcement of this material customer contract the ASX market announcements team requested further identification of the 'major international pharmaceutical company' and 'existing AtCor Medical client' as referenced in the announcement. In all other aspects the announcement was consistent with the disclosure requirements of material customer contracts under ASX Guidance Note 8.

The identity of customers is a matter that CardieX has previously treated as being commercially sensitive to its business and has also not announced due to the confidentiality clauses contained in customer supplier agreements.

CardieX understands its obligations in complying with the ASX listing rules and is pleased to announce the identity of its customer relationship with AstraZeneca AB.

AstraZeneca AB is a global, science-led biopharmaceutical business. Their innovative medicines are used by millions of patients worldwide.

CardieX is pleased to confirm its customer relationship with AstraZeneca AB, being just one example of the quality customers in the AtCor Medical business.



For more information please contact:

Chief Executive Officer

Craig Cooper

Ph: +61 429 993 399

ccooper@cardiex.com

Investor Relations

Peter Taylor

Ph: +61 412 036 231

peter@nwrcommunications.com.au

About CardieX

CardieX is a Sydney based global health technology company focused on developing technology solutions for large-scale population health disorders.